Sanofi buys Kadmon, adding important transplant drug to range
In August, the drugmaker agreed to buy its mRNA development partner, Translate Bio, for $3.2bn
08 September 2021 - 09:03
byThomas Mulier
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Sanofi has agreed to buy Kadmon Holdings for $1.9bn, adding a maker of immune therapies to expand its drug portfolio.
Kadmon investors will receive $9.50 a share in cash, which is 79% more than Tuesday’s closing price, the companies said Wednesday. Kadmon’s board has approved the deal.
Kadmon focuses on diseases that lack treatments, and it makes Rezurock, a therapy approved in the US for chronic graft-versus-host disease. Sanofi said it will add the drug to its transplant business, which makes immunosuppresants.
Sanofi has been on the acquisition trail. In August, the French drugmaker agreed to acquire its messenger-RNA development partner Translate Bio for $3.2bn, expanding in the technology behind some of the world’s top-selling Covid-19 vaccines.
Bloomberg News. More stories like this are available on bloomberg.com
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Sanofi buys Kadmon, adding important transplant drug to range
In August, the drugmaker agreed to buy its mRNA development partner, Translate Bio, for $3.2bn
Sanofi has agreed to buy Kadmon Holdings for $1.9bn, adding a maker of immune therapies to expand its drug portfolio.
Kadmon investors will receive $9.50 a share in cash, which is 79% more than Tuesday’s closing price, the companies said Wednesday. Kadmon’s board has approved the deal.
Kadmon focuses on diseases that lack treatments, and it makes Rezurock, a therapy approved in the US for chronic graft-versus-host disease. Sanofi said it will add the drug to its transplant business, which makes immunosuppresants.
Sanofi has been on the acquisition trail. In August, the French drugmaker agreed to acquire its messenger-RNA development partner Translate Bio for $3.2bn, expanding in the technology behind some of the world’s top-selling Covid-19 vaccines.
Bloomberg News. More stories like this are available on bloomberg.com
US drug firms say $26bn opioid settlement will proceed
Covid vax maker eyes malaria, TB
Moderna says vaccine 93% effective for six months after second jab
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Pharmacies likely to be the next target for opioid settlements
Access to mRNA vaccines remains a challenge for many countries
EU gives nod to India’s Covishield vaccine
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.